| SAREPTA THERAPEUTICS |
| USA |
| Gesundheit |
| US8036071004 / A1J1BH |
| AB3A (Frankfurt) / SRPT (NASDAQ) |
| FRA:AB3A, ETR:AB3A, AB3A:GR, NASDAQ:SRPT |
| - |
| https://www.sarepta.com/ |
|
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based t..
>Volltext.. |
| 1849.47 Mio. EUR |
| 2074.65 Mio. EUR |
| 1719.03 Mio. EUR |
| -0.3 Mio. EUR |
| -231.69 Mio. EUR |
| -2.28 EUR |
| 910.6 Mio. EUR |
| 497.29 Mio. EUR |
| 81.8 Mio. EUR |
| 1.57 |
| -17.94% |
| -373.59% |
| - |
| - |
| - |
| - |
| SAREPTA, AVI BIOPHARMA |
| 21.09.26 |
|